Pierre Beauparlant
Chief Executive Officer at PreciThera, Inc.
Profile
Pierre Beauparlant is currently the Chief Executive Officer & Director at PreciThera, Inc. and a Venture Partner at Sanderling Management CO LLC since 2017.
He previously worked as the Vice President-Research & Scientific Development at Gemin X Pharmaceuticals US, Inc. and as a Product Manager at Novartis Pharmaceuticals Corp.
Dr. Beauparlant holds a doctorate degree from McGill University and a graduate degree from the University of Montréal, which he received in 1991.
Pierre Beauparlant active positions
| Companies | Position | Start |
|---|---|---|
Sanderling Management CO LLC
 Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Private Equity Investor | 01/03/2017 |
PreciThera, Inc.
 PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Chief Executive Officer | - |
Former positions of Pierre Beauparlant
| Companies | Position | End |
|---|---|---|
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Chief Tech/Sci/R&D Officer | - |
Training of Pierre Beauparlant
| McGill University | Doctorate Degree |
| University of Montréal | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Finance |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
PreciThera, Inc.
PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Health Technology |
- Stock Market
- Insiders
- Pierre Beauparlant
